Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Capital Expenditures (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Capital Expenditures for 11 consecutive years, with $126000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 37.93% to $126000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 million, a 95.67% increase, with the full-year FY2025 number at $1.1 million, up 95.67% from a year prior.
  • Capital Expenditures was $126000.0 for Q4 2025 at Intellia Therapeutics, up from $29000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $12.4 million in Q4 2023 to a low of -$6.6 million in Q3 2023.
  • A 5-year average of $1.5 million and a median of $525000.0 in 2024 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: crashed 140.78% in 2022, then skyrocketed 2332.14% in 2023.
  • Intellia Therapeutics' Capital Expenditures stood at $2.9 million in 2021, then crashed by 119.42% to -$557000.0 in 2022, then surged by 2332.14% to $12.4 million in 2023, then tumbled by 98.37% to $203000.0 in 2024, then plummeted by 37.93% to $126000.0 in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Capital Expenditures are $126000.0 (Q4 2025), $29000.0 (Q3 2025), and $892000.0 (Q2 2025).